Loop ligation-assisted endoscopic resection of a gastrointestinal stromal tumor in the gastric fundus

Author(s):  
Vincent Zimmer ◽  
Bert Bier
2018 ◽  
Vol 26 (3) ◽  
pp. 215-217
Author(s):  
João Fernandes ◽  
Diogo Libânio ◽  
Sílvia Giestas ◽  
Tarcísio Araújo ◽  
José Ramada ◽  
...  

Endoscopy ◽  
2021 ◽  
Author(s):  
Timothée Wallenhorst ◽  
Jérémie Jacques ◽  
Astrid Lièvre ◽  
Mael Pagenault ◽  
Guillaume Bouguen ◽  
...  

2013 ◽  
Vol 50 (4) ◽  
pp. 244-250 ◽  
Author(s):  
Gustavo Lemos PELANDRÉ ◽  
Maria Célia DJAHJAH ◽  
Emerson Leandro GASPARETTO ◽  
Marcelo Souto NACIF ◽  
Edson MARCHIORI ◽  
...  

ContextGastrointestinal stromal tumors are uncommon abdominal neoplasms and can affect any portion of the gastrointestinal tract.ObjectivesDescribe the tomographic findings of the gastrointestinal stromal tumor of gastric origin, correlating it with the mitotic index.MethodsTwenty-one patients were selected within the period of January 2000 and 2008, with histopathological and immunohistochemical diagnosis of gastric gastrointestinal stromal tumors, who presented computed tomography done before the treatment. The tomographic variables analyzed were lesion topography, dimensions, contours, morphology, pattern and intensity enhancement through venous contrast, growth pattern, invasion of adjacent organs, presence of ulceration, fistula, calcifications, infiltration of mesenteric fat, lymphadenopathy and metastasis. The mitotic index was determined through optic microscopy, counting the number of mitosis figures in 50 high power fields.ResultsThe tumors were located in the body (66.7%) or gastric fundus (33.3%), with dimensions varying between 4.2 and 21.2 cm (average of 10.5 cm). The growth was predominantly extraluminal (47.6%) or intra/extra luminal (28.6%). The enhancement by venous contrast was heterogeneous in 66.7%. The statistical analysis showed that irregular morphology (P = 0.027) and infiltration of mesenteric fat (P = 0.012) presented correlation with the high mitotic index.ConclusionsIn the present study, most part of the tumors were located in the gastric body, with average size of 10.5 cm, presenting central hypo dense area, heterogeneous enhancement through contrast and predominantly extra luminal growth. Irregular morphology and infiltration of mesenteric fat present statistical correlation with high mitotic level.


Author(s):  
A. Ledo-Rodríguez ◽  
J. L. Ulla-Rocha ◽  
R. Baltar-Arias ◽  
S. Vázquez-Rodríguez ◽  
W. Díaz-Saa ◽  
...  

2015 ◽  
Vol 81 (5) ◽  
pp. AB254-AB255
Author(s):  
Min Jae Yang ◽  
Sun Gyo Lim ◽  
Sung Jae Shin ◽  
Kee Myung Lee

Endoscopy ◽  
2017 ◽  
Vol 49 (S 01) ◽  
pp. E11-E13 ◽  
Author(s):  
Hejun Zhou ◽  
Yuyong Tan ◽  
Chunlian Wang ◽  
Jingbo Yang ◽  
Yuqian Zhou ◽  
...  

2018 ◽  
Vol 34 ◽  
pp. 15-19
Author(s):  
Sen Liu ◽  
Hongyu Liu ◽  
Yunlong Dong ◽  
Fengbiao Wang ◽  
Huijuan Wang ◽  
...  

Gastric carcinoma (GC) with gastrointestinal stromal tumor (GIST) is encountered very rarely in the clinic, and few cases have been reported in the literature. Here, we present a case involving a 72-year-old man who was diagnosed with gastric antrum adenocarcinoma accompanied by neuroendocrine differentiation and a GIST in the fundus, according to a preoperative examination and postoperative pathology. The patient then underwent a distal radical gastrectomy and GIST resection. After the operation, the patient was administered combined chemo-radiotherapy and subsequently underwent a 9-month follow-up examination. The gene mutations involved in this case were explored via high-throughput sequencing. The high-throughput gene mutation analysis indicated an exon5 mutation in the TP53 gene and copy number amplification of FGF19, CCND1, and FGFR2 in the gastric antrum adenocarcinoma. A gene sequencing analysis of the gastric fundus stromal tumor demonstrated an exon11 non-frame shift deletion mutation in the KIT gene. These findings suggested that this patient’s cancer might be sensitive to AZD1775 (a TP53-targeted drug) or targeted drugs such as FGF19, CCND1 and FGFR2, and should be sensitive to imatinib.


Sign in / Sign up

Export Citation Format

Share Document